# Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL

> **NCT06052696** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 500 (estimated)

## Conditions studied

- Vulvar HSIL
- HPV

## Interventions

- **DRUG:** Gardasil 9 Suspension for Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06052696
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06052696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06052696, "Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06052696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*